Rabbit anti-Human VEGF Receptor 1 Polyclonal Antibody | anti-VEGFR1 antibody

VEGF Receptor 1 (Flt1, VEGFR1) Soluble (Vascular Endothelial Growth Factor Receptor 1, sVEGFR-1, sFlt1) (APC)

Cat. Num. AAA6505586

• Reactivity: Human
• Applications: Western Blot
• Purity: Purified by Immunoaffinity chromatography.
• Synonyms: VEGF Receptor 1; Polyclonal Antibody; VEGF Receptor 1 (Flt1; VEGFR1) Soluble (Vascular Endothelial Growth Factor Receptor 1; sVEGFR-1; sFlt1) (APC); anti-VEGFR1 antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Isotype: IgG
• Specificity: Recognizes the soluble form of human VEGF Receptor 1.
• Purity/Purification: Purified by Immunoaffinity chromatography.
• Form/Format: Supplied as a liquid in PBS, pH 7.2. No preservatives added. Labeled with Allophycocyanin (APC).

• Applicable Applications for anti-VEGFR1 antibody: FLISA, Western Blot (WB)
• Application Notes: Applications are based on unconjugated antibody.
• Immunogen: Synthetic peptide derived from the C-terminal region of the soluble form of the human VEGF Receptor 1 (sVEGFR-1, sFlt-1) protein.
• Conjugate: APC
• Note: Preservative Free
• Preparation and Storage: Store product at 4 degree C in the dark. DO NOT FREEZE! Stable at 4 degree C for 12 months after receipt as an undiluted liquid. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: APC conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

Related Product Information for anti-VEGFR1 antibody

Angiogenesis, the formation of new blood vessels, is regulated by the balance between positive and negative endothelial regulatory factors. Vascular endothelial factor receptor-1 (VEGFR-1), also known as FMS-like tyrosine kinase 1 (Flt-1), is a transmembrane receptor tyrosine kinase with high affinity for vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) (1-3). Binding of VEGF to VEGFR-1 produces receptor dimerization and subsequent signal transduction. Full length VEGFR-1 is characterized by the presence of seven extracellular immunoglobulin-like domains containing the ligand binding region, a single short transmembrane sequence, and an intracellular region with a tyrosine kinase domain (2). VEGF receptors are expressed by vascular endothelial cells and peripheral blood monocytes (4), and have also been observed in colon carcinoma cell lines and colorectal cancer liver metastases (5). In addition to the full-length form of the receptor, a soluble form (sVEGFR-1 or sFlt-1) is generated by alternative splicing of Flt-1 mRNA. This naturally occurring, soluble form of VEGFR-1 is truncated on the C-terminal side of the sixth extracellular Ig-like domain (6), and has been described in various locations, including the serum and plasma of normal males and females, the serum of pregnant women, placenta, and breast tumor tissues (7,8). Soluble VEGFR-1 is an antagonist of VEGF action and an inhibitor of the VEGF signaling pathway, which has been characterized as one of the most important endothelial regulators in human tumor angiogenesis.

Product Categories/Family for anti-VEGFR1 antibody

Antibodies; Receptors

References

1. Devries C, et al. Science 255:989-991, 1992. 2. Thomas KA. J Biol Chem 271(2):603-606, 1996. 3. Neufeld G, et al. FASEB J 13:9-22, 1999. 4. Sawano A, et al. Blood 97(3):785-791, 2001. 5. Warren RS, et al. J Clin Invest 95(4):1789-1797, 1995. 6. Kendall R, Thomas KA. PNAS 90:10705-10709, 1993. 7. Barleon B, et al. Angiogenesis 4(2):143-154, 2001. 8. Toi M, et al. Int J Cancer 98(1):14-18, 2002. 9. Hornig C, et al. Lab Invest 80(4):443-454, 2000.